190 related articles for article (PubMed ID: 26036636)
1. Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.
Zheng YZ; Wang L; Hu X; Shao ZM
Oncotarget; 2015 Sep; 6(26):22985-95. PubMed ID: 26036636
[TBL] [Abstract][Full Text] [Related]
2. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
Liu YR; Jiang YZ; Yu KD; Shao ZM
Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
[TBL] [Abstract][Full Text] [Related]
4. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
5. Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer.
Wo JY; Chen K; Neville BA; Lin NU; Punglia RS
J Clin Oncol; 2011 Jul; 29(19):2619-27. PubMed ID: 21606424
[TBL] [Abstract][Full Text] [Related]
6. Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.
Schinkel JK; Zahm SH; Jatoi I; McGlynn KA; Gallagher C; Schairer C; Shriver CD; Zhu K
Cancer Causes Control; 2014 Aug; 25(8):959-68. PubMed ID: 24839049
[TBL] [Abstract][Full Text] [Related]
7. Clinical Features and Survival of Single Hormone Receptor-Positive Breast Cancer: A Population-Based Study of 531,605 Patients.
Lv M; Mao Y; Song Y; Wang Y; Liu X; Wang X; Nie G; Wang H
Clin Breast Cancer; 2020 Oct; 20(5):e589-e599. PubMed ID: 32565109
[TBL] [Abstract][Full Text] [Related]
8. Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
Wang C; Zhou Y; Zhu H; Huang W; Chen Z; Mao F; Lin Y; Zhang X; Shen S; Zhong Y; Li Y; Sun Q
Cancer Med; 2018 Nov; 7(11):5420-5430. PubMed ID: 30277006
[TBL] [Abstract][Full Text] [Related]
9. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.
Bardia A; Olson JE; Vachon CM; Lazovich D; Vierkant RA; Wang AH; Limburg PJ; Anderson KE; Cerhan JR
Breast Cancer Res Treat; 2011 Feb; 126(1):149-55. PubMed ID: 20669045
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
11. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
12. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
[TBL] [Abstract][Full Text] [Related]
13. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
Dunnwald LK; Rossing MA; Li CI
Breast Cancer Res; 2007; 9(1):R6. PubMed ID: 17239243
[TBL] [Abstract][Full Text] [Related]
14. Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
Wei JL; Zhang JX; Fu DY
World J Surg Oncol; 2018 Dec; 16(1):236. PubMed ID: 30558615
[TBL] [Abstract][Full Text] [Related]
15. The effect of laterality and primary tumor site on cancer-specific mortality in breast cancer: a SEER population-based study.
Bao J; Yu KD; Jiang YZ; Shao ZM; Di GH
PLoS One; 2014; 9(4):e94815. PubMed ID: 24740002
[TBL] [Abstract][Full Text] [Related]
16. A population-based study of Kurdish breast cancer in northern Iraq: hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data.
Runnak MA; Hazha MA; Hemin HA; Wasan AA; Rekawt RM; Michael HD
BMC Womens Health; 2012 Jun; 12():16. PubMed ID: 22727195
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognostic effect of hormone receptor subtype on breast cancer.
Hwang KT; Kim J; Jung J; Kim BH; Park JH; Jeon SY; Hwang KR; Roh EY; Park JH; Kim SJ
Breast Cancer Res Treat; 2020 Jan; 179(1):139-151. PubMed ID: 31595365
[TBL] [Abstract][Full Text] [Related]
18. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
19. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
20. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database.
Anderson WF; Chu KC; Chatterjee N; Brawley O; Brinton LA
J Clin Oncol; 2001 Jan; 19(1):18-27. PubMed ID: 11134191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
